EUCTR2014-003950-15-DK进行中（未招募）不适用
A single center, open label clinical trial investigating the long-term efficacy of rhLAMAN (recombinant human alpha-mannosidase or Lamazym) treatment in subjects with alpha-Mannosidosis who previously participated in Lamazym trials
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- Zymenex A/S
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.The subject must have participated in the phase 1 trial (EudraCT number: 2010-022084-36), phase 2a trial (EudraCT number: 2010-022085-26), phase 2b trial (EudraCT number: 2011-004355-40) or phase 3 trial (EudraCT number: 2012-000979-17)
- •2.The subject must still be receiving weekly intravenous infusions of Lamazym according to the AfterCare Program
- •3.The Subject or subjects legally authorized guardian(s) must provide signed, informed consent prior to performing any trial-related activities
- •4.The subject and his/her guardian(s) must have the ability to comply with the protocol
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 7
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 13
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1.History of bone marrow transplantation
- •2.Presence of known clinically significant cardiovascular, hepatic, pulmonary or renal disease or other medical conditions that, in the opinion of the Investigator, would preclude participation in the trial. Subjects unable to perform the motor tests independently from support are permitted to participate in the trial and will be evaluated for the remnant non motor endpoints
- •3.Any other medical condition or serious intercurrent illness, or extenuating circumstance that, in the opinion of the investigator, would preclude participation in the trial
- •4.Pregnant and/or lactating women cannot participate in the trial. Concerning women of child bearing potential (WOCBP), the investigators will decide whether or not there is a need for contraception. This assessment will be done through interviews with the patient and parents.
- •5.Participation in other interventional trials testing IMP, including rhLAMAN-07 (EudraCT number: 2013-000336-97) and rhLAMAN-09 (EudraCT number: 2013-000321-31) trials with Lamazym
- •6.Pause of the IMP for 2 consecutive weeks during the last month. Subjects are allowed to be re-screened
研究者
相似试验
已完成
不适用
The effect of Rhodiola rosea Extract WS 1375 on attention and mental resource allocatioISRCTN29449049Dr. Willmar Schwabe GmbH & Co. KG (Germany)50
已完成
不适用
A single centre, open label trial investigating the absorption, metabolism and excretion of somapacitan after single subcutaneous dosing in healthy male subjectsgroeihormoondeficientiegrowth hormone deficiencyNL-OMON42854ovo Nordisk A/S7
已完成
不适用
A pilot study to evaluate the safety and advantages of CurQfen on brain function in middle aged to elderly people.CTRI/2018/03/012393Akay Flavours and Aromatics Private Limited6
已完成
不适用
An open label, single institute, single arm trial of efficacy and safety of the anti-RANKL monoclonal antibody (Denosumab) for patients with steroid-induced osteoporosissteroid induced osteoporosisJPRN-UMIN000011461Juntendo University130
招募中
1 期
Open-label single-arm, multicenter clinical trial to evaluate patient acceptability of a new CREON formulation of Pancreas Powder gastro-resistant pellets in patients with cystic fibrosis suffering from pancreatic exocrine insufficiency.patients with cystic fibrosis suffering from pancreatic exocrine insufficiencyMedDRA version: 21.0Level: PTClassification code: 10079428Term: Cystic fibrosis gastrointestinal disease Class: 100000004850CTIS2023-503256-27-00MEDA Pharma GmbH & Co. KG80